Recent Updates
Recently added Catalysts

Sotera Health Company

SHCFDA catalysts, PDUFA dates & pipeline intelligence
$15.91
▼ -0.3 · -1.85%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full SHC financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $13.0952W HIGH $19.85
Volume
1.73 M
Value Traded
27.57 M
Short % Float
5.88%
Days to Cover
7.5
-4.21%Week
-10.47%1 Month
-18.7%3 Month
+1.6%6 Month
+0.76%1 Year
-27.58%5 Year
-42%All Time

Cash Data

Unlock SHC cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
4.54 B
EPS (TTM)
0.61
P/E Ratio
26.16
Ent. Value
6.27 B
Total Shares
285.63 M
Float Shares
279.62 M
Insiders
2.11%
Institutions
101.06%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Unlock every SHC catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

SHC Catalyst Timeline

Dated clinical, regulatory and corporate events for Sotera Health Company

Unlock the full SHC catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How SHC actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
No matching catalysts
Unlock all SHC historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

No drug pipeline

Sotera Health Company is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.

Clinical Trial Results

Readouts, endpoints and source filings for every SHC program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
Scroll for more · summaries link to the source press release
Unlock every SHC trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock SHC insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Petras Michael B. Jr.Director, Officer (Executive Chairman)Sell -294,515 397,912 held$18.50 08/17/2026
Unlock the full SHC insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
Avidity Partners 1.5 % (7.1 %) 69.71 M 2.96 M 24.47% ( 582.00 K)
Unlock every fund holding SHC
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in SHC
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see SHC ownership
Insider and institutional ownership, quarter by quarter.

SHC Short Interest

Shares sold short, counted twice a month.

5.88%
Short % of Float
of tradable shares sold short
16.4M
Shares Sold Short
+2.2% vs prior count
7.5 High
Days to Cover
trading days of normal volume to buy every short share back
2.2M
Avg Daily Volume
the average used for days to cover
Unlock SHC short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-12-18
Unlock SHC option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live SHC option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock SHC options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How SHC ranks across every disease it competes in

Competitive Position is a premium feature
See how SHC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

SHC News

SHC
Nov 3, 2026
SHCGeneral
▼ -9.6%on this news

Sotera Health Reports Solid Third-Quarter and Year-to-Date 2026 Results

Sotera Health reported a 4.4% increase in Q3 2026 net revenues, totaling $58 million in net income. Adjusted EBITDA rose by 3.9%, with a 12% increase in Adjusted EPS to $0.29. The company reaffirmed its full-year growth outlook, despite a revenue decline in its Nordion segment due to Co-60 harvest timing.

Read more →
SHC
Oct 21, 2026
SHCConferences/Events

Sotera Health Announces Third-Quarter 2026 Earnings Release Date

Sotera Health Company plans to release its third-quarter financial results on November 3, 2026. The results will be shared before market opening, followed by a conference call at 9:00 a.m. ET. Investors can access a live webcast and updates on the company's website.

Read more →
SHC
Aug 6, 2026
SHCGeneral
▲ +5.2%on this news

Sotera Health Delivers Strong Second-Quarter and First-Half 2026 Results and Raises FY 2026 Outlook

Sotera Health Company reported robust financial results for Q2 and the first half of 2026, with net revenues up 9.2% and net income significantly increasing to $54 million. The company also raised its full-year outlook for both revenue and adjusted EBITDA growth, reflecting strong performance across its business segments. CEO Alton Shader expressed confidence in the company's growth strategy and customer relationships.

Read more →
SHC
Jul 23, 2026
SHCConferences/Events

Sotera Health Announces Second-Quarter 2026 Earnings Release Date

Sotera Health Company has announced the release date for its second-quarter 2026 earnings, set for August 6, 2026. The financial results will be available before market opening, followed by a conference call at 9:00 a.m. EDT. Investors can access a live webcast of the call and find updates on the company's website.

Read more →
SHC
May 11, 2026
SHCGeneral

Sotera Health Announces Secondary Offering of Common Stock

Sotera Health Company has announced a secondary offering of 31,838,253 shares of common stock, which are being sold by affiliates of Warburg Pincus LLC and GTCR LLC. The company itself will not be selling any shares or receiving any proceeds from this offering, as it will only cover associated expenses. Goldman Sachs & Co. LLC is serving as the underwriter for this transaction. The announcement emphasizes potential risks related to the offering that could affect shareholder value.

Read more →
SHC
May 5, 2026
SHCGeneral

Sotera Health Delivers Strong First-Quarter 2026 Results and Reaffirms 2026 Outlook

Sotera Health reported a strong financial performance for Q1 2026, with net revenues increasing by 10% year-over-year. The company achieved a net income of $27 million, a significant improvement from a loss in Q1 2025. Adjusted EBITDA also saw a 10.5% increase, and the company reaffirmed its full-year growth outlook. The positive results were driven by strong performance in its Sterigenics and Nordion segments.

Read more →
SHC
May 5, 2026
SHCGeneral

Sotera Health Announces Leadership Transition

Sotera Health announced a leadership transition with Alton Shader set to become CEO on May 26, 2026, succeeding Michael B. Petras, Jr. Petras will assume the role of Executive Chairman and continue to guide the company. Shader, with extensive experience in the medical industry, aims to build on Sotera's success in providing critical healthcare services.

Read more →
SHC
Apr 21, 2026
SHCGeneral

Sotera Health Announces First-Quarter 2026 Earnings Release Date

Sotera Health Company has announced that it will release its financial results for the first quarter of 2026 before the market opens on May 5, 2026. Following the announcement, management will conduct a conference call to discuss the operating and financial results at 9:00 a.m. EDT. The company continues to emphasize its commitment to providing essential sterilization solutions and advisory services to the healthcare sector.

Read more →
SHC
Mar 16, 2026
SHCGeneral

Sotera Health Appoints Kenneth D. Krause to the Board of Directors

Sotera Health Company has appointed Kenneth D. Krause as an independent director to its Board of Directors, effective March 16, 2026. Krause brings over ten years of experience as a public company CFO and a strong background in strategy and financial governance. He will serve on the Audit and Litigation Committees. Additionally, Dean S. Mihas has resigned from the Board due to a reduction in the number of directors designated by certain stockholders, ending his service since October 2020.

Read more →
SHC
Feb 24, 2026
SHCGeneral

Sotera Health Delivers 20th Consecutive Year of Revenue Growth and Provides 2026 Outlook

Sotera Health Company reported a 4.6% increase in fourth-quarter 2025 net revenues, marking its 20th consecutive year of revenue growth. The company achieved a net income of $35 million for the quarter and $78 million for the full year, driven by strong demand for its sterilization and lab testing services. Looking ahead, Sotera Health is optimistic about its financial outlook for 2026.

Read more →
SHC
Feb 17, 2026
SHCConferences/Events

Sotera Health Announces Fourth-Quarter and Full-Year 2025 Earnings Release Date

Sotera Health Company has announced the release date for its fourth-quarter and full-year 2025 earnings. The financial results will be available before the market opens on February 24, 2026, followed by a conference call at 9:00 a.m. ET to discuss the results. The event will be accessible via a live webcast.

Read more →
SHC
Feb 5, 2026
SHCGeneral

Sotera Health Appoints Richard Kyle to the Board of Directors

Sotera Health has appointed Richard G. Kyle as an independent director on its Board of Directors. Kyle, who previously served as CEO of The Timken Company, brings extensive experience in global operations and financial management. He will also participate in the Leadership Development and Compensation Committee and the Nominating and Corporate Governance Committee.

Read more →
SHC
Jan 12, 2026
SHCConferences/Events

Sotera Health to Showcase Continued Revenue Growth and Strategic Value Creation at 44th Annual J.P. Morgan Healthcare Conference

Sotera Health Company presented a positive outlook at the 44th Annual J.P. Morgan Healthcare Conference, projecting 2025 revenue to exceed $1.16 billion, marking over 20 years of growth. CEO Michael B. Petras, Jr. emphasized the company's robust financial position and commitment to customer service. However, the company faces several risks, including potential supply chain disruptions and ongoing legal challenges that could affect financial stability. The full-year results and future outlook are set to be discussed on February 24, 2026.

Read more →
SHC
Jan 7, 2026
SHCConferences/Events

Sotera Health to Present at the 44th Annual J.P. Morgan Healthcare Conference

Sotera Health Company announced its participation in the 44th Annual J.P. Morgan Healthcare Conference, scheduled for January 12, 2026. The company's management will present at 1:30 p.m. ET and will also hold investor meetings. A live webcast of the presentation will be available on their website, with a replay accessible within 48 hours.

Read more →
SHC
Nov 4, 2025
SHCGeneral

Sotera Health Reports Strong Third-Quarter and Year-to-Date 2025 Results

Sotera Health Company reported robust financial results for Q3 and year-to-date 2025, with net revenues rising by 9.1% to $311 million and net income increasing significantly. The company achieved double-digit growth in Adjusted EBITDA and reaffirmed its revenue outlook for the year while raising its Adjusted EBITDA forecast. However, pending settlements related to ethylene oxide claims pose potential risks.

Read more →
SHC
Oct 21, 2025
SHCConferences/Events

Sotera Health Announces Third-Quarter 2025 Earnings Release Date

Sotera Health Company has announced the date for its third-quarter 2025 earnings release, scheduled for November 4, 2025. The company will provide financial results for the quarter ended September 30, 2025, before the market opens. Following the release, a conference call will be held to discuss the results and highlights.

Read more →

About Sotera Health Company

Broadview Heights, OH 3,000 employees soterahealth.com
Headquarters9100 SOUTH HILLS BLVD, SUITE 300, BROADVIEW HEIGHTS, OH, 44147
BIOPHARMAWATCH ELITE
Trade the next SHC catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime